NASDAQ OMX

CloudCraze Named a Visionary in Gartner Magic Quadrant for Digital Commerce

Dela

Cloud-based B2B commerce platform recognized for its completeness of vision and ability to execute

CHICAGO, May 03, 2017 (GLOBE NEWSWIRE) -- CloudCraze, an enterprise digital commerce solution built natively on Salesforce, has once again been named a Visionary in the 24 April 2017 Gartner Magic Quadrant for Digital Commerce.

"We believe it's an honor to be named a Visionary by Gartner for the second year in a row. For us, this recognition demonstrates that we are a disruptive force in the digital commerce market and are providing significant value for our customers through fast implementation and robust B2B functionalities," said Chris Dalton, CEO of CloudCraze. "We feel this reaffirms that our Salesforce-native cloud-based approach to digital commerce is exactly what B2B organizations need to be successful in the shift towards digital."

CloudCraze delivers robust B2B commerce built natively on Salesforce, the world's #1 CRM and most-trusted cloud platform. It enables native capabilities for incorporating Salesforce Sales Cloud and Service Cloud functionality into the digital commerce platform, providing a single view of the customer by sharing data and businesses processes across CRM and commerce systems. Centralized data empowers sales representatives with a clearer picture of customer needs and purchasing habits to cross-sell, upsell and personalize offerings more effectively.

CloudCraze provides strong B2B capabilities and faster site launches. Simplified implementation through an agile approach enables faster time-to-market, resulting in an earlier payback period for B2B organizations. Additionally, CloudCraze's depth of B2B functionality address the complex nature of the B2B commerce industry. The platform's B2B-specific capabilities include contract pricing for multiple contracts at once, order and pricing override functionality based on a person's role, and account-based viewing settings.

The Gartner Magic Quadrant for Digital Commerce analyzed 21 vendors on their completeness of vision and ability to execute. Vendors are assessed on market presence and company viability, product functionality and product agility. The vendors with the highest aggregated evaluation scores in the inclusion criteria are included in the report and placed on a market spectrum of leaders, challengers, visionaries and niche players.

"Over the past year, we've continued to expand our ability to deliver a customer-centric digital commerce solution as a Salesforce Platinum ISV Partner and through strategic partnerships with leaders in digital innovation, including Adobe and Deloitte Digital," Dalton furthered. "Our commitment to regular product enhancements, including our recent Spring '17 release, will ensure we're continuing to provide the fastest, most flexible B2B commerce platform on the market."

This announcement comes on the heels of CloudCraze's recognition in The Forrester Wave(TM): B2B Commerce Suites, Q1 2017. To learn more about CloudCraze's recently launched Spring '17 release and its new product, CloudCraze Exchange, click here.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About CloudCraze

CloudCraze delivers robust B2B commerce native on Salesforce. It allows businesses to generate online revenue fast and easily scale for growth. Its Customer-First Commerce model puts the customer at the core, informing every interaction with data across commerce, sales, marketing, service and more. With the trusted Salesforce infrastructure and core capabilities, CloudCraze provides infinite flexibility to extend functionality, add products and channels, and conduct billions of dollars in transactions anywhere. CloudCraze powers Customer-First Commerce for industry leaders such as AB InBev, Barry-Callebaut, Coca-Cola, Ecolab, GE, Kellogg's, L'Oreal, Symantec, and WABCO.

CloudCraze is funded by Insight Venture Partners and Salesforce Ventures.

CloudCraze is recognized in The Forrester Wave(TM): B2B Commerce Suites, Q1 2017 and as a Visionary in the Gartner Magic Quadrant for Digital Commerce 2017. CloudCraze is a Salesforce Platinum ISV Partner.

Media contacts
Rachel Gulden
Senior Account Executive
rachel.gulden@walkersands.com
312.267.0530

Sarah Traxler
Senior Director, Marketing
sarah.traxler@cloudcraze.com
312.752.4473 x1003



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CloudCraze via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00Pressmeddelande

AUSTIN, Texas, Sept.  21, 2017  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech

At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58Pressmeddelande

LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service.  As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al

Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00Pressmeddelande

Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00Pressmeddelande

Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea

Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00Pressmeddelande

Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu

Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23Pressmeddelande

DANVERS, Mass., Sept.  20, 2017  (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum